For instance, immune checkpoint blockade (ICB), which has revolutionized the treatment of solid tumors, currently results in a 60% response rate in those melanoma patients treated with anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) (4). Here, CTLA4 is linked to melanoma.